🔗 Share this article

Given that the US continues making unprecedented adjustments to its vaccination recommendations, a particular individual has surfaced in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports medicine doctor and public health researcher who initially gained attention by questioning COVID-19 vaccinations throughout the pandemic and has concentrated on alleged deaths following COVID-19 immunization in her recent time at the FDA.

Proposed Shifts to Childhood Immunization Schedule

Public health authorities planned to reveal major changes to the pediatric vaccination calendar earlier this month, synchronizing the US with Denmark’s national calendar, sources say – a significant shift that would put the US at odds with much of the global community with insufficient data for benefit. The planned update has been pushed back until the coming year.

In place of the director of the vaccine center, Tracy Beth Høeg is listed to speak at the meeting. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth appointee to head the division this calendar year.

A New Direction at the FDA

Høeg's temporary position could signify a strengthened alliance between the pharmaceutical and vaccine centers as Dr. Høeg and Prasad consolidate power at the regulatory agency – and it signals a renewed priority upon reevaluating already-approved vaccines at the FDA.

Høeg has often pushed for discontinuing some childhood immunization guidelines in the US to become more like Denmark's approach, a nation with comprehensive healthcare and a population approximately the population of Wisconsin’s.

In her initial statements, she has persisted in emphasizing on vaccines – usually the responsibility of Dr. Prasad, chief of the FDA’s vaccine center – instead of drug regulation.

Questions Over Qualifications

Dr. Høeg has little discernible track record in medication creation, regulation or leadership, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the commissioner and the vaccine center since March.

“She doesn’t seem to have the necessary background” for leading the drug-regulation department, stated a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She lacks experience in running a sizeable institution. She lacks background in drug approvals.”

Former commissioners of the center would “understand regulatory frameworks and the underlying principles of drug development”, commented Dr. Janet Woodcock. “Frankly, she lacks the sort of resume that previous people who led the center have had.”

The drug center has an enormous range of responsibilities at the FDA, Woodcock emphasized.

“Everybody just pays attention on the innovative therapies, but the generic drug division authorizes a multitude of generic drugs. There is also a biosimilars program, OTC medication office and so forth, and every single one need to be looked after,” Dr. Woodcock said. “The area you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Additionally, a significant management element to the position, which supervises in excess of 5,000 staff members. “It’s a massive management job, if you execute it properly,” she concluded.

Response and Controversial Programs

In response to questions about Høeg’s qualifications and whether this selection signifies more teamwork among agency officials on vaccines, a representative stated that the “concerns stem from inaccurate assumptions”.

“Her resume aligns with the duties of her job,” the spokesperson explained, pointing to the period Dr. Høeg spent guiding the agency head on “drug safety and oversight research, including predictive safety algorithms and immunization monitoring”.

As acting director, Dr. Høeg takes over the commissioner’s controversial expedited review system, a contentious expedited medication authorization process that apparently worried her former heads. “By what process are these medications being chosen for this fast-track system? Who is making the decisions?” Dr. Howard said. “There is a lot of lack of transparency occurring at the FDA right now.”

In general, he said, “the Food and Drug Administration appears to be shifting towards more relaxed rules of all drugs, aside from vaccines.”

Documented Past Work on Vaccines

With immunizations, Dr. Høeg has a clearer, if concerning, history, some experts said. She authored a study using unverified crowd-sourced reports to determine the rate of heart inflammation after COVID-19 vaccination. She counseled the state of Florida top health official Dr. Joseph Ladapo, who allegedly have modified findings to suggest Covid vaccinations are pose a greater threat than they are.

Among her “wish list” for the current administration encompassed revising guidelines for new vaccines and halting “unnecessary” vaccines, she remarked post-election on a podcast. At the FDA, Dr. Høeg has allegedly proposed preventing teenage boys from getting COVID-19 vaccines.

“She’s an thorough true believer who starts off with her beliefs and reverse-engineers to retrofit the data in a extremely deceptive, untruthful manner,” Dr. Howard argued.

Consolidating Power and a “Push for Payback”

Høeg became part of other contrarians, {like|